Safety evaluation of Bifidobacterium breve IDCC 4401 isolated from infant feces for use as a commercial probiotic
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Previously, our research group isolated Bifidobacterium breve IDCC4401 from infant feces as a potential probiotic. For this study, we evaluated the safety of B. breve IDCC4401 using genomic and phenotypic analyses. Whole genome sequencing was performed to identify genomic characteristics and investigate the potential presence of genes encoding virulence, antibiotic resistance, and mobile genetic elements. Phenotypic analyses including antibiotic susceptibility, enzyme activity, production of biogenic amines (BAs), and proportion of D-/L-lactate were evaluated using E-test, API ZYM test, high-performance liquid chromatography (HPLC), and D-/L-lactic acid assay respectively. The genome of B. breve IDCC4401 consists of 2,426,499 bp with a GC content of 58.70% and 2,016 coding regions. Confirmation of the genome as B. breve was provided by its 98.93% similarity with B. breve DSM20213. Furthermore, B. breve IDCC4401 genes encoding virulence and antibiotic resistance were not identified. Although B. breve IDCC4401 showed antibiotic resistance against vancomycin, we confirmed that this was an intrinsic feature since the antibiotic resistance gene was not present. B. breve IDCC4401 showed leucine arylamidase, cystine arylamidase, α-galactosidase, β-galactosidase, and α-glucosidase activities, whereas it did not show production of harmful enzymes such as β-glucosidase and β-glucuronidase. In addition, B. breve IDCC4401 did not produce any tyramine, histamine, putrescine, cadaverine, or 2-phenethylamine, which are frequently detected BAs during fermentation. B. breve IDCC4401 produced 95.08% of L-lactate and 4.92% of Dlactate. Therefore, our findings demonstrate the safety of B. breve IDCC 4401 as a potential probiotic for use in the food industry.
Abstract
Previously, our research group isolated Bifidobacterium breve IDCC4401 from infant feces as a potential probiotic. For this study, we evaluated the safety of B. breve IDCC4401 using genomic and phenotypic analyses. Whole genome sequencing was performed to identify genomic characteristics and investigate the potential presence of genes encoding virulence, antibiotic resistance, and mobile genetic elements. Phenotypic analyses including antibiotic susceptibility, enzyme activity, production of biogenic amines (BAs), and proportion of D-/L-lactate were evaluated using E-test, API ZYM test, high-performance liquid chromatography (HPLC), and D-/L-lactic acid assay respectively. The genome of B. breve IDCC4401 consists of 2,426,499 bp with a GC content of 58.70% and 2,016 coding regions. Confirmation of the genome as B. breve was provided by its 98.93% similarity with B. breve DSM20213. Furthermore, B. breve IDCC4401 genes encoding virulence and antibiotic resistance were not identified. Although B. breve IDCC4401 showed antibiotic resistance against vancomycin, we confirmed that this was an intrinsic feature since the antibiotic resistance gene was not present. B. breve IDCC4401 showed leucine arylamidase, cystine arylamidase, α-galactosidase, β-galactosidase, and α-glucosidase activities, whereas it did not show production of harmful enzymes such as β-glucosidase and β-glucuronidase. In addition, B. breve IDCC4401 did not produce any tyramine, histamine, putrescine, cadaverine, or 2-phenethylamine, which are frequently detected BAs during fermentation. B. breve IDCC4401 produced 95.08% of L-lactate and 4.92% of Dlactate. Therefore, our findings demonstrate the safety of B. breve IDCC 4401 as a potential probiotic for use in the food industry.
참고문헌 (41)
- Report of a joint FAO, "WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria", FAO, 2001
- Kechagia M, "Health benefits of probiotics : a review", ISRN Nutr, 2013, pp.PMC4045285~ (2013)
- 임현정, "Antimicrobial and Immunomodulatory Effects of Bifidobacterium Strains: A Review", Journal of Microbiology and Biotechnology, 30(12), pp.1793~1800 (2020), 한국미생물·생명공학회[DOI]
- Ku S, "Biosafety assessment of Bifidobacterium animalis subsp. lactis AD011used for human consumption as a probiotic microorganism", Food Control, 117, pp.106985~ (2020)
- O'Shea EF, "Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms : bacteriocins and conjugated linoleic acid", Int. J. Food Microbiol, 152, pp.189~205 (2012)
- Jin H, "Isolation and characterization of high exopolysaccharide-producing Weissella confusa VP30 from young children’s feces", Microb. Cell Fact, 18, pp.110~ (2019)
- "Probiotics market size, share and trends analysis report by product (food and beverages, dietary supplements), by ingredient (bacteria, yeast), by end use, by distribution channel, and segment forecasts, 2019-2025" (2019)[URL]
- Ciorba M, "A gastroenterologist's guide to probiotics", Clin. Gastroenterol. Hepatol, 10, pp.960~968 (2012)
- Lee J-H, "Genomic insights into bifidobacteria", Microbiol. Mol. Biol. Rev, 74, pp.378~416 (2010)
- Zuo F, "Characterization and in vitro properties of potential probiotic Bifidobacterium strains isolated from breast-fed infant feces", Ann. Microbiol, 66, pp.1027~1037 (2016)
- Tissier H, "Recherches sur la flore intestinale des nourrissons:(état normal et pathologique)", pp.1900
- Zinedine A, "Isolation and characterization of strains of Bifidobacteria with probiotic proprieties in vitro", WJDFS, 2, pp.28~34 (2007)
- Sgorbati B, "The genera of lactic acid bacteria", pp.279~306 (1995), Springer
- Koirala S, "Probiotics-based foods and beverages as future foods and their overall safety and regulatory claims", Future Foods, 3, pp.100013~ (2021)
- Working group report on drafting guidelines for the evaluation of probiotics in food, "FAO", World Health Organization and Food and Agriculture Organization of the United Nations, ~ (2002)
- Kim MJ, "Safety evaluations of Bifidobacterium bifidum BGN4 and Bifidobacterium longum BORI", Int. J. Mol. Sci, 19, pp.1422~ (2018)
- EFSA, "Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance", EFSA J, 10, pp.1~10 (2012)
- FAO, "Probiotics in food: Health and nutritional properties and guidelines for evaluation", World Health Organization and Food and Agriculture Organization of the United Nations, ~ (2006)
- McArthur AG, "The comprehensive antibiotic resistance database", Antimicrob. Agents Chemother, 57, pp.3348~3357 (2013)
- Chen L, "VFDB 2016 : hierarchical and refined dataset for big data analysis--10 years on", Nucleic Acids Res, 44, pp.D694~697 (2016)
- Arndt D, "PHASTER : a better, faster version of the PHAST phage search tool", Nucleic Acids Res, 44, pp.W16~W21 (2016)
- Deepika Priyadarshani WM, "Screening selected strains of probiotic lactic acid bacteria for their ability to produce biogenic amines(histamine and tyramine)", Int. J. Food Sci. Technol, 46, pp.2062~2069 (2011)
- Charteris W, "Antibiotic susceptibility of potentially probiotic Bifidobacterium isolates from the human gastrointestinal tract", Lett. Appl. Microbiol, 26, pp.333~337 (1998)
- Álvarez-Cisneros YM, "Antimicrobial Resistance-A Global Threat", pp.53~73 (2018), IntechOpen
- Elisha BG, "Analysis of genes encoding D-alanine : D-alanine ligase-related enzymes in Leuconostoc mesenteroides and Lactobacillus spp", Gene, 152, pp.79~83 (1995)
- Martinez D, "API ZYM assay to evaluate enzyme fingerprinting and microbial functional diversity in relation to soil processes", Biol. Fertil Soils, 52, pp.77~89 (2016)
- Desjardins M-L, "Growth of bifidobacteria and their enzyme profiles", J. Dairy Sci, 73, pp.299~307 (1990)
- Chevalier P, "Detection of Bifidobacterium species by enzymatic methods", J. Appl. Bacteriol, 68, pp.619~624 (1990)
- 한유리, "Production of α- and β-Galactosidases from Bifidobacterium longum subsp. longum RD47", Journal of Microbiology and Biotechnology, 24(5), pp.675~682 (2014), 한국미생물·생명공학회[DOI]
- De Preter V, "Effect of dietary intervention with different pre-and probiotics on intestinal bacterial enzyme activities", Eur. J. Clin. Nutr, 62, pp.225~231 (2008)
- Cole C, "The effect of dietary fat and yoghurt on colonic bacterial enzymes(β-glucosidase and β-glucuronidase)associated with colon cancer", Food Microbiol, 4, pp.77~81 (1987)
- Kim DH, "Intestinal bacterial β-glucuronidase activity of patients with colon cancer", Arch Pharm. Res, 24, pp.564~567 (2001)
- Barbieri F, "Biogenic amine production by lactic acid bacteria : a review", Foods, 8, pp.17~ (2019)
- Ekici K, "Detection of common biogenic amines in fermented sausage produced in Turkey", Data Brief, 20, pp.1360~1362 (2018)
- Lorencová E, "Production of biogenic amines by lactic acid bacteria and bifidobacteria isolated from dairy products and beer", Int. J. Food Sci. Technol, 47, pp.2086~2091 (2012)
- Pohanka M, "D-Lactic acid as a metabolite : Toxicology, diagnosis, and detection", Biomed. Res. Int, 2020, pp.3419034~ (2020)
- Lee DK, "Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients", Clin. Res. Hepatol. Gastroenterol, 39, pp.237~244 (2015)
- Prasirtsak B, "D-Lactic acid fermentation performance and the enzyme activity of a novel bacterium Terrilactibacillus laevilacticus SK5–6", Ann. Microbiol, 69, pp.1537~1546 (2019)
- Ewaschuk JB, "D-lactate in human and ruminant metabolism", J. Nutr, 135, pp.1619~1625 (2005)
- Muñoz JAM, "Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections", Appl. Environ. Microbiol, 77, pp.8775~8783 (2011)
- Hansen C., "Generally recognized as safe (GRAS) determination for the intended use of Bifidobacterium animalis ssp", lactis BB12®FDA, ~ (2019)